

Report of the Trustees and
Unaudited Financial Statements
for the Year Ended 31st December 2020
for
European Parkinson's Disease Association

A4G LLP
Kings Lodge
London Road
West Kingsdown
Sevenoaks
Kent
TN15 6AR

Contents of the Financial Statements
for the Year Ended 31st December 2020

	Page
Report of the Trustees	1 to 5
Independent Examiner's Report	6
Statement of Financial Activities	7
Statement of Financial Position	8
Statement of Cash Flows	9
Notes to the Statement of Cash Flows	10
Notes to the Financial Statements	11 to 19
Detailed Statement of Financial Activities	20 to 22

European Parkinson's Disease Association

Report of the Trustees **for the Year Ended 31st December 2020**

The trustees who are also directors of the charity for the purposes of the Companies Act 2006, present their report with the financial statements of the charity for the year ended 31st December 2020. The trustees have adopted the provisions of Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (effective 1 January 2019).

Introduction

2020 has been a very difficult year for the whole world, and in particular organisations working in the non-profit sector - including many EPDA member organisations - have been hit particularly hard by the COVID-19 pandemic. In spite of this, the EPDA has been able to adapt to the 'new normal' and achieve a series of accomplishments that, we believe, allow us to lay the foundations for a positive post-COVID-19 outlook.

In the past 12 months, we completed the process to substantially improve the EPDA's internal governance - reforming our Statutes (with the help and collaboration of our Members) and striving for increased transparency and democracy. We also acquired new member organisations and started a process to improve and boost the two-way communication with our members - the first step being an important survey to better understand our members' opinions, needs and challenges.

We have continued to develop our relationships with the treatment industry, securing a record number of funding partners going into 2021 and engaging in a number of win-win partnered projects that will benefit the Parkinson's community - in many cases leading to better treatment options for people living with the condition.

We continued the roll-out of our EU advocacy strategy and developed new EPDA strategic projects that are set to be carried out over the next four years.

Last but not least, we produced and delivered some impressive online resources (developed both independently and in partnership with the treatment industry) to provide support to the Parkinson's community during the COVID-19 lockdown periods.

The EPDA Team would like to thank the EPDA Board members for contributing with their knowledge, expertise and constant commitment to the positive results of the projects and activities detailed below.

Governance

Statutes:

- o Amendments proposed and discussed in late 2019, voted by Members in early 2020
- o Most proposed amends approved by a majority of the Members
- o Statutes changes ratified by the AGM in September 2020
- o Amendment procedure to be finalised in 2021

Board:

- o A new President and Vice-President elected
- o Three new full Board members (former observers) elected by the AGM
- o Three new Board observers appointed in 2020

Results

- o Increased transparency and democracy
- o Smoother decision-making process and internal functioning
- o Improved expertise and representation in the Board

EPDA strategy

EPDA strategy reviewed by the EPDA Board at the end of 2020.

Four strategic goals still fit for purpose:

- a. To advocate for people with Parkinson's and their families to get the right information at the right time throughout their Parkinson's journey.
- b. To strive for healthcare systems where people with Parkinson's receive early and appropriate treatment and individualised care.
- c. To raise awareness of the complexity of Parkinson's and the impact it has on people's quality of life.

European Parkinson's Disease Association

Report of the Trustees **for the Year Ended 31st December 2020**

d. To support the global Parkinson's community in the search for a cure.

Three new strategic themes for the next three years:

- a. Uniting Europe
- b. Big data
- c. Research

Membership

Three new member organisations approved by the AGM in 2020

Member's survey

- o Most member organisations are 'satisfied' with being EPDA members
- o Most member organisations think the EPDA six-year strategy is fit for purpose
- o Most member organisations think the current level of communication with the EPDA is 'good' or 'excellent'

Completion of a set of guidelines aimed at Parkinson's organisations in the event of a shortage of medicines (this idea was initiated as a result of the panel discussion at the 2019 Members' Meeting)

Involvement of 18 member organisations in the WPC clinical trials survey, and eight in the subsequent in-depth conference calls

Members' Meeting 2020 (virtual): participation and engagement from 20 members

Member-specific activities being planned for 2021:

- o Exclusive EPDA member virtual roundtable events
- o EPDA membership grant scheme

Results

- o Improved two-way communication between EPDA and MOs
- o Development of EPDA-members partnered activities on topics that are fundamental for the European Parkinson's community

The EPDA would be delighted to hear about any initiatives from our members and partners that we could support, help advertise and promote, or advise on. If you need any help, please do get in touch and ask us!

Team improvements

A new Project Manager

A new Communications Lead

Team restructuring: increasing hours and streamlining roles and tasks for all Team members

Results

- o Improved expertise within the Team
- o Smoother internal functioning

EPDA exposure

High-profile international congresses:

- o Continued partnership and collaboration with WPC 2022, which will lead to very exciting EPDA-led activities in 2021 and 2022
- o MDS 2020: presentation of abstract about the EPDA-Air Liquide survey on the challenges of Parkinson's carers
- o INSIGHT into Parkinson's 2020: presentation on the EPDA survey on the challenges of Parkinson's carers

Medical/scientific journals:

- o Advertisements and highlights from our website and the Parkinson's Disease Composite Scale (Oruen, touchNeurology)

Results

Increased knowledge and awareness of the EPDA and Parkinson's in the medical/scientific community

Increased knowledge and awareness of the EPDA work in the Parkinson's community

Treatment industry collaboration

Funding (including work done in 2020 that has led to partnerships in 2021). Note: details below correct as at 8 February 2021

- o Diamond partners:
 - AbbVie (2020)

European Parkinson's Disease Association

Report of the Trustees **for the Year Ended 31st December 2020**

Boston Scientific (2020 and 2021)
Britannia Pharmaceuticals (2021)
Kyowa Kirin (2021)
Sunovion (2020 and 2021)

o Gold partners:
Abbott (2021)
Air Liquide (2020 and 2021)
BIAL (2020 and 2021)
Medtronic (2020 and 2021)
Merz (2020 and 2021)
Servier (2021)
UCB (2020)

o Silver partners:
Biogen (2021)
EverPharma (2020)
Servier (2020)
Theravance Biopharma (2021)
UCB (2021)
Zambon (2020 and 2021)

o Tech partners:
GE Healthcare (2020)
Insightec (2020)

o Other partners:
Herantis (2020)
Lundbeck (2020)

Partnered projects include:

- o **Abbott:** development of a content campaign to raise awareness of the DBS options available to people with Parkinson's
- o **AbbVie:** EPDA Board members supporting AbbVie in the development of its Parkinson's research investigations
- o **Air Liquide:** carers' survey (dissemination of results in 2020 and 2021)
- o **Bial:** collaboration with BIAL on the Keep it ON video awareness campaign, developing a series of awareness videos involving people with Parkinson's from five European countries
- o **Bial:** development of the Keep ON Moving! dual-task video exercise project in collaboration with BIAL
- o **Britannia Pharmaceuticals:** development of a content campaign to raise awareness of the non-oral treatment options available to people with Parkinson's
- o **Herantis and TreatER:** EU-funded project concluded and results published in a virtual webinar held in November 2020
- o **Kyowa Kirin:** participation of the EPDA in an advisory panel on patient organisations engagement organised by Kyowa Kirin
- o **Medtronic:** support of Medtronic's new Percept device launch, and review of World Parkinson's Day awareness materials
- o **Merz:** survey on sialorrhea in Parkinson's developed in collaboration with Merz (carried out in 2020, results expected in 2021)
- o **Servier:** organisation of a workshop with people with Parkinson's, carers and advocates (preparation in 2020, virtual workshop to be held in 2021) in collaboration with Servier
- o **Sunovion:** awareness communication campaign on Sunovion's clinical trial of sublingual apomorphine - developed in 2020, to be launched in early 2021

Results

Increased participation of the Parkinson's community (represented by the EPDA) in industry activities
Ultimately, the development of better treatment, support and care solutions for people with Parkinson's

Research

TreatER project

- o Long-time collaboration with Herantis Pharma and lead academic universities
- o Started in 2017
- o Results presented at a virtual scientific conference in November 2020

Sunovion CTH-302 trial

- o Collaboration with treatment company and research institutions in six European countries

European Parkinson's Disease Association

Report of the Trustees **for the Year Ended 31st December 2020**

- o Raising awareness of the clinical trial opportunities available to the Parkinson's community

Servier clinical trial design

- o Involving the Parkinson's community in the guiding, planning, design and development of Servier's upcoming clinical trial
- o Organisation of a collaborative workshop with people with Parkinson's, carers and patient advocates

WPC clinical trials interest group

- o Working with Parkinson's associations from around the world on surveys and conference calls in order to gather information about the barriers and opportunities for Parkinson's communities interested in getting involved in research

Results

Increased involvement of the Parkinson's community (represented by the EPDA, EPDA members and Parkinson's advocates) in the planning and design of treatment research

More inclusive, effective and patient-friendly clinical trials

Ultimately, the development of better treatment solutions for people with Parkinson's

Advocacy

2020 was the year to prepare the ground for the EPDA's outreach for the next four years. A new EU came into power in 2020 and we have been assessing how they view health and indeed whether they know about Parkinson's.

We are completing an in-depth political mapping of who's who in the Institutions directly but also indirectly influencing/impacting health policy. We have undertaken a decision-makers survey to assess their understanding of the disease and we have reached out to them to both introduce ourselves and to lay out our needs and asks.

We have developed a number of hooks for future advocacy campaigning in EU-Brussels around the role of carers as a follow-up to the EPDA/Air Liquide survey; around the role of pesticides and their impact on Parkinson's, and most recently on the EU's review of the pharmaceutical industry which will be a on-going issue for the year to come, looking at, for example, equal access to medicines, shortages of medicines, and many other key topics

The EPDA has been engaged closely with EFNA and played a role in developing their strategy for the Brain, Mind and Pain EP intergroup

We have developed the EU-Brussels Political Advocacy bi-monthly newsletter aimed at member organisations and other EPDA stakeholders

Ongoing support to the PD Avengers advocacy group throughout 2020 and into 2021

Results

Increased awareness of the complexity of Parkinson's and the impact it has on people's quality of life

Ultimately, better policies and public interventions in support of people with Parkinson's, their families and carers

Resources and digital communication

Sleep and Parkinson's awareness campaign: initiated in Q4 2020 and to be launched in 2021

EPDA Exercise Cast: our own online video exercise series for people with Parkinson's (which led directly to the incredibly successful Keep ON Moving! exercise video series we created in collaboration with our partner, Bial)

#BrainLifeGoals: educational video for HCPs focusing on cognitive-motor exercise programmes

EPDA website

- o Nearly 370,000 users and more than 850,000 page views
- o Traffic from more than 200 countries
- o High engagement to the About Parkinson's and Living Well sections

Parkinson's Life

o Parkinson's Life podcast awarded 'Best Global Audio Campaign of the Year' at the Global Content Awards 2020

o Nearly 270,000 users and 400,000 page views

EPDA strategic communications review - initiated in 2020, due to be finalised and implemented in 2021

Results

o Increased awareness of the complexity of Parkinson's and the impact it has on people's quality of life

o Delivery of high-quality information and resources to the Parkinson's community

European Parkinson's Disease Association

Report of the Trustees **for the Year Ended 31st December 2020**

FINANCIAL REVIEW

Going concern

At the time of approving the financial statements, the Trustees have a reasonable expectation that the charity has adequate resources to continue in operational existence for the foreseeable future. Thus the Trustees continue to adopt the going concern basis of accounting in preparing the financial statements.

The Association's reserve policy is to hold reserves only to cover a period of 6 months administration costs. No additional reserves are intended to be held. Further analysis of restricted and unrestricted funds can be found in note 14.

STRUCTURE, GOVERNANCE AND MANAGEMENT

The charity was established by a charitable trust deed on 25th April 1998 in Belgium and registered as a Charitable Incorporated Organisation in the UK on 19th August 2015.

The trustees have had regard to the Charity Commission's guidance on public benefit.

REFERENCE AND ADMINISTRATIVE DETAILS

Registered Company number

CE004367 (England and Wales)

Registered Charity number

1163211

Registered office

Kings Lodge
London Road
West Kingsdown
Sevenoaks
Kent
TN15 6AR

Trustees

Mr K Onarheim (resigned 1.9.20)
Ms M E Graham
Ms S Lindvall (resigned 1.9.20)
Ms V Clark
Mr D J Lavender MBE
Ms V A Buxton
Ms P Gilmore
J Domingos (appointed 1.9.20)
C P Likar (appointed 1.9.20)
T Shaish (appointed 1.9.20)

Independent Examiner

A4G LLP
Kings Lodge
London Road
West Kingsdown
Sevenoaks
Kent
TN15 6AR

Approved by order of the board of trustees on and signed on its behalf by:

.....
Ms V Clark - Trustee

**Independent Examiner's Report to the Trustees of
European Parkinson's Disease Association**

Independent examiner's report to the trustees of European Parkinson's Disease Association ('the Company')

I report to the charity trustees on my examination of the accounts of the Company for the year ended 31st December 2020.

Responsibilities and basis of report

As the charity's trustees of the Company (and also its directors for the purposes of company law) you are responsible for the preparation of the accounts in accordance with the requirements of the Companies Act 2006 ('the 2006 Act').

Having satisfied myself that the accounts of the Company are not required to be audited under Part 16 of the 2006 Act and are eligible for independent examination, I report in respect of my examination of your charity's accounts as carried out under section 145 of the Charities Act 2011 ('the 2011 Act'). In carrying out my examination I have followed the Directions given by the Charity Commission under section 145(5) (b) of the 2011 Act.

Independent examiner's statement

Since your charity's gross income exceeded £250,000 your examiner must be a member of a listed body. I can confirm that I am qualified to undertake the examination because I am a registered member of ACA which is one of the listed bodies.

I have completed my examination. I confirm that no matters have come to my attention in connection with the examination giving me cause to believe:

1. accounting records were not kept in respect of the Company as required by section 386 of the 2006 Act; or
2. the accounts do not accord with those records; or
3. the accounts do not comply with the accounting requirements of section 396 of the 2006 Act other than any requirement that the accounts give a true and fair view which is not a matter considered as part of an independent examination; or
4. the accounts have not been prepared in accordance with the methods and principles of the Statement of Recommended Practice for accounting and reporting by charities (applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102)).

I have no concerns and have come across no other matters in connection with the examination to which attention should be drawn in this report in order to enable a proper understanding of the accounts to be reached.

Caroline Coleman
ACA
A4G LLP
Kings Lodge
London Road
West Kingsdown
Sevenoaks
Kent
TN15 6AR

Date:

European Parkinson's Disease Association

Statement of Financial Activities **(Incorporating an Income and Expenditure Account)** **for the Year Ended 31st December 2020**

	Notes	Unrestricted funds £	Restricted funds £	2020 Total funds £	2019 Total funds £
INCOME AND ENDOWMENTS FROM					
Donations and legacies	4	28,283	-	28,283	26,626
Charitable activities	5				
Member organisation and board meetings		-	-	-	22,374
Other income		-	-	-	1,895
Investments		174	-	174	313
Publications		-	-	-	6,774
Project Income		-	-	-	52,557
Core Income		352,597	178,911	531,508	255,664
Total		<u>381,054</u>	<u>178,911</u>	<u>559,965</u>	<u>366,203</u>
EXPENDITURE ON					
Charitable activities	6				
Member organisation and board meetings		22,762	-	22,762	40,223
Advocacy communication and project development		213,615	5,505	219,120	72,356
Grant Funded projects		67,809	10,299	78,108	100,025
Support costs		186,018	11,334	197,352	129,098
Governance costs		1,000	-	1,000	1,000
Other		<u>1,326</u>	<u>-</u>	<u>1,326</u>	<u>-</u>
Total		<u>492,530</u>	<u>27,138</u>	<u>519,668</u>	<u>342,702</u>
Net gains/(losses) on investments		<u>3,213</u>	<u>(10,942)</u>	<u>(7,729)</u>	<u>(2,285)</u>
NET INCOME/(EXPENDITURE)		<u>(108,263)</u>	<u>140,831</u>	<u>32,568</u>	<u>21,216</u>
RECONCILIATION OF FUNDS					
Total funds brought forward		<u>119,912</u>	<u>182,767</u>	<u>302,679</u>	<u>281,463</u>
TOTAL FUNDS CARRIED FORWARD		<u><u>11,649</u></u>	<u><u>323,598</u></u>	<u><u>335,247</u></u>	<u><u>302,679</u></u>

The notes form part of these financial statements

European Parkinson's Disease Association

Statement of Financial Position
31st December 2020

	Notes	2020 £	2019 £
CURRENT ASSETS			
Debtors	11	133,500	68,704
Cash at bank and in hand		<u>457,222</u>	<u>411,317</u>
		590,722	480,021
CREDITORS			
Amounts falling due within one year	12	(255,475)	(177,342)
		<u>335,247</u>	<u>302,679</u>
NET CURRENT ASSETS			
		<u>335,247</u>	<u>302,679</u>
TOTAL ASSETS LESS CURRENT LIABILITIES		<u>335,247</u>	<u>302,679</u>
NET ASSETS		<u>335,247</u>	<u>302,679</u>
FUNDS	14		
Unrestricted funds		11,650	119,912
Restricted funds		<u>323,597</u>	<u>182,767</u>
TOTAL FUNDS		<u>335,247</u>	<u>302,679</u>

The charitable company is entitled to exemption from audit under Section 477 of the Companies Act 2006 for the year ended 31st December 2020.

The members have not required the company to obtain an audit of its financial statements for the year ended 31st December 2020 in accordance with Section 476 of the Companies Act 2006.

The trustees acknowledge their responsibilities for

- (a) ensuring that the charitable company keeps accounting records that comply with Sections 386 and 387 of the Companies Act 2006 and
- (b) preparing financial statements which give a true and fair view of the state of affairs of the charitable company as at the end of each financial year and of its surplus or deficit for each financial year in accordance with the requirements of Sections 394 and 395 and which otherwise comply with the requirements of the Companies Act 2006 relating to financial statements, so far as applicable to the charitable company.

The financial statements were approved by the Board of Trustees and authorised for issue on
and were signed on its behalf by:

.....
Ms V Clark - Trustee

.....
Mr D J Lavender MBE - Trustee

The notes form part of these financial statements

European Parkinson's Disease Association

Statement of Cash Flows
for the Year Ended 31st December 2020

	Notes	2020 £	2019 £
Cash flows from operating activities			
Cash generated from operations	1	<u>53,634</u>	<u>28,365</u>
Net cash provided by operating activities		<u>53,634</u>	<u>28,365</u>
Cash flows from investing activities			
Sale of fixed asset investments		<u>(7,729)</u>	<u>(2,285)</u>
Net cash used in investing activities		<u>(7,729)</u>	<u>(2,285)</u>
Change in cash and cash equivalents in the reporting period		45,905	26,080
Cash and cash equivalents at the beginning of the reporting period		<u>411,317</u>	<u>385,237</u>
Cash and cash equivalents at the end of the reporting period		<u><u>457,222</u></u>	<u><u>411,317</u></u>

The notes form part of these financial statements

Notes to the Statement of Cash Flows
for the Year Ended 31st December 2020

1. RECONCILIATION OF NET INCOME TO NET CASH FLOW FROM OPERATING ACTIVITIES

	2020	2019
	£	£
Net income for the reporting period (as per the Statement of Financial Activities)	32,568	21,216
Adjustments for:		
Losses on investments	7,729	2,285
(Increase)/decrease in debtors	(64,796)	20,936
Increase/(decrease) in creditors	<u>78,133</u>	<u>(16,072)</u>
Net cash provided by operations	<u>53,634</u>	<u>28,365</u>

2. ANALYSIS OF CHANGES IN NET FUNDS

	At 1.1.20	Cash flow	At 31.12.20
	£	£	£
Net cash			
Cash at bank and in hand	<u>411,317</u>	<u>45,905</u>	<u>457,222</u>

Notes to the Financial Statements
for the Year Ended 31st December 2020

1. CHARITY INFORMATION

European Parkinson's Disease Association is a Charitable Incorporated Organisation registered in the UK on 19 August 2015.

2. ACCOUNTING POLICIES

Accounting convention

The accounts have been prepared in accordance with the charity's trust deed, the Charities Act 2011, the Charities and Trustee Investment (Scotland) Act 2005, the Charities Accounts (Scotland) Regulations 2006 (as amended) and "Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102)" (as amended for accounting periods commencing from 1 January 2016). The charity is a Public Benefit Entity as defined by FRS 102.

The financial statements have departed from the Charities (Accounts and Reports) Regulations 2008 only to the extent required to provide a true and fair view. This departure has involved following the Statement of Recommended Practice for charities applying FRS 102 rather than the version of the Statement of Recommended Practice which is referred to in the Regulations but which has since been withdrawn.

The financial statements are prepared in sterling, which is the functional currency of the charity. Monetary amounts in these financial statements are rounded to the nearest £.

The financial statements have been prepared under the historical cost convention, modified to include the revaluation of freehold properties and to include investment properties and certain financial instruments at fair value. The principal accounting policies adopted are set out below.

Incoming resources

Income is recognised when the charity is legally entitled to it after any performance conditions have been met, the amounts can be measured reliably, and it is probable that income will be received.

Cash donations are recognised on receipt. Other donations are recognised once the charity has been notified of the donation, unless performance conditions require deferral of the amount. Income tax recoverable in relation to donations received under Gift Aid or deeds of covenant is recognised at the time of the donation.

Legacies are recognised on receipt or otherwise if the charity has been notified of an impending distribution, the amount is known, and receipt is expected. If the amount is not known, the legacy is treated as a contingent asset.

Turnover is measured at the fair value of the consideration received or receivable and represents amounts receivable for goods and services provided in the normal course of business, net of discounts, VAT and other sales related taxes.

Charitable funds

Unrestricted funds are available for use at the discretion of the Trustees in furtherance of their charitable objectives unless the funds have been designated for other purposes.

Restricted funds are subject to specific conditions by donors as to how they may be used. The purposes and uses of the restricted funds are set out in the notes to the financial statements.

Endowment funds are subject to specific conditions by donors that the capital must be maintained by the charity.

Financial instruments

The charity has elected to apply the provisions of Section 11 'Basic Financial Instruments' and Section 12 'Other Financial Instruments Issues' of FRS 102 to all of its financial instruments.

Financial instruments are recognised in the charity's balance sheet when the charity becomes party to the contractual provisions of the instrument.

Notes to the Financial Statements - continued
for the Year Ended 31st December 2020

2. ACCOUNTING POLICIES - continued

Financial instruments

Financial assets and liabilities are offset, with the net amounts presented in the financial statements, when there is a legally enforceable right to set off the recognised amounts and there is an intention to settle on a net basis or to realise the asset and settle the liability simultaneously.

Basic financial assets

Basic financial assets, which include debtors and cash and bank balances, are initially measured at transaction price including transaction costs and are subsequently carried at amortised cost using the effective interest method unless the arrangement constitutes a financing transaction, where the transaction is measured at the present value of the future receipts discounted at a market rate of interest. Financial assets classified as receivable within one year are not amortised.

Basic financial liabilities

Basic financial liabilities, including creditors and bank loans are initially recognised at transaction price unless the arrangement constitutes a financing transaction, where the debt instrument is measured at the present value of the future payments discounted at a market rate of interest. Financial liabilities classified as payable within one year are not amortised.

Debt instruments are subsequently carried at amortised cost, using the effective interest rate method.

Trade creditors are obligations to pay for goods or services that have been acquired in the ordinary course of operations from suppliers. Amounts payable are classified as current liabilities if payment is due within one year or less. If not, they are presented as non-current liabilities. Trade creditors are recognised initially at transaction price and subsequently measured at amortised cost using the effective interest method.

Derecognition of financial liabilities

Financial liabilities are derecognised when the charity's contractual obligations expire or are discharged or cancelled.

Employee benefits

The cost of any unused holiday entitlement is recognised in the period in which the employee's services are received.

Termination benefits are recognised immediately as an expense when the charity is demonstrably committed to terminate the employment of an employee or to provide termination benefits.

Foreign exchange

Transactions in currencies other than pounds sterling are recorded at the rates of exchange prevailing at the dates of the transactions. At each reporting end date, monetary assets and liabilities that are denominated in foreign currencies are retranslated at the rates prevailing on the reporting end date. Gains and losses arising on translation are included in net income/(expenditure for the period.

Leases

Rentals payable under operating leases, including any lease incentives received, are charged as an expense on a straight line basis over the term of the relevant lease.

Irrecoverable vat

Irrecoverable VAT is charged against the expenditure heading for which it was incurred.

Notes to the Financial Statements - continued
for the Year Ended 31st December 2020

3. CRITICAL ACCOUNTING JUDGEMENTS AND KEY SOURCES OF ESTIMATION UNCERTAINTY

In the application of the charity's accounting policies, the Trustees are required to make judgements, estimates and assumptions about the carrying amount of assets and liabilities that are not readily apparent from other sources. The estimates and associated assumptions are based on historical experience and other factors that are considered to be relevant. Actual results may differ from these estimates.

The estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognised in the period in which the estimate is revised where the revision affects only that period, or in the period of the revision and future periods where the revision affects both current and future periods.

4. DONATIONS AND LEGACIES

	2020	2019
	£	£
Members fees	23,904	24,408
Donations	<u>4,379</u>	<u>2,218</u>
	<u>28,283</u>	<u>26,626</u>

5. INCOME FROM CHARITABLE ACTIVITIES

	2020	2019
	£	£
Member organisation meeting	-	22,374
Other income	-	1,895
Investments	174	313
Publication income	-	6,774
Project income	-	52,557
Core income	<u>531,508</u>	<u>255,664</u>
	<u>531,682</u>	<u>339,577</u>

6. CHARITABLE ACTIVITIES COSTS

	Direct Costs	Support costs (see note 7)	Totals
	£	£	£
Member organisation and board meetings	22,762	-	22,762
Advocacy communication and project development	215,978	3,142	219,120
Grant Funded projects	78,108	-	78,108
Support costs	68,988	128,364	197,352
Governance costs	<u>-</u>	<u>1,000</u>	<u>1,000</u>
	<u>385,836</u>	<u>132,506</u>	<u>518,342</u>

Notes to the Financial Statements - continued
for the Year Ended 31st December 2020

7. SUPPORT COSTS

	Management £	Finance £	Other £	Governance costs £	Totals £
Advocacy communication and project development	3,142	-	-	-	3,142
Support costs	5,637	65,095	57,632	-	128,364
Governance costs	-	-	-	1,000	1,000
	<u>8,779</u>	<u>65,095</u>	<u>57,632</u>	<u>1,000</u>	<u>132,506</u>

Support costs, included in the above, are as follows:

				2020	2019
	Advocacy communication and project development £	Support costs £	Governance costs £	Total activities £	Total activities £
Advertising	3,142	-	-	3,142	-
Fundraising	-	5,637	-	5,637	14,926
Wages	-	25,099	-	25,099	8,693
Bank charges	-	178	-	178	-
Financial administration	-	30,818	-	30,818	15,326
Accountancy fees	-	5,000	-	5,000	4,760
Bookkeeping costs	-	4,000	-	4,000	-
General expenditure	-	12,714	-	12,714	13,062
Administration costs	-	44,918	-	44,918	8,436
Independent examination costs	-	-	1,000	1,000	1,000
	<u>3,142</u>	<u>128,364</u>	<u>1,000</u>	<u>132,506</u>	<u>66,203</u>

8. TRUSTEES' REMUNERATION AND BENEFITS

Ms M E Graham received fees totalling £24,703 (2019: £16,747) in connection with her role as strategic advisor. The payments have been made in accordance with the charity's constitution and approved by the other trustees.

9. STAFF COSTS

	2020 £	2019 £
Wages and salaries	<u>25,099</u>	<u>8,693</u>
	<u>25,099</u>	<u>8,693</u>

Payments to defined contribution retirement benefit schemes are charged as an expense as they fall due.

The average monthly number of employees during the year was as follows:

	2020	2019
Administration	<u>2</u>	<u>2</u>

Notes to the Financial Statements - continued
for the Year Ended 31st December 2020

9. STAFF COSTS - continued

The number of employees whose employee benefits (excluding employer pension costs) exceeded £60,000 was:

	2020	2019
£60,001 - £70,000	<u>1</u>	<u>-</u>

10. COMPARATIVES FOR THE STATEMENT OF FINANCIAL ACTIVITIES

	Unrestricted funds £	Restricted funds £	Total funds £
INCOME AND ENDOWMENTS FROM			
Donations and legacies	26,628	(2)	26,626
Charitable activities			
Member organisation and board meetings	22,374	-	22,374
Other income	1,895	-	1,895
Investments	313	-	313
Publications	6,774	-	6,774
Project Income	39,316	13,241	52,557
Core Income	174,249	81,415	255,664
Total	271,549	94,654	366,203
EXPENDITURE ON			
Charitable activities			
Member organisation and board meetings	40,223	-	40,223
Advocacy communication and project development	72,356	-	72,356
Grant Funded projects	4,200	95,825	100,025
Support costs	126,880	2,218	129,098
Governance costs	1,000	-	1,000
Total	244,659	98,043	342,702
Net gains/(losses) on investments	<u>(2,285)</u>	<u>-</u>	<u>(2,285)</u>
NET INCOME/(EXPENDITURE)	24,605	(3,389)	21,216
RECONCILIATION OF FUNDS			
Total funds brought forward	95,309	186,154	281,463
TOTAL FUNDS CARRIED FORWARD	<u>119,914</u>	<u>182,765</u>	<u>302,679</u>

Notes to the Financial Statements - continued
for the Year Ended 31st December 2020

11. DEBTORS: AMOUNTS FALLING DUE WITHIN ONE YEAR

	2020	2019
	£	£
Trade debtors	120,397	68,477
Prepayments and accrued income	<u>13,103</u>	<u>227</u>
	<u>133,500</u>	<u>68,704</u>

12. CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR

	2020	2019
	£	£
Trade creditors	68,718	43,913
Social security and other taxes	1,878	5,637
Net wages	7,769	5,568
Pension	255	256
Accruals and deferred income	<u>176,855</u>	<u>121,968</u>
	<u>255,475</u>	<u>177,342</u>

13. ANALYSIS OF NET ASSETS BETWEEN FUNDS

	Unrestricted funds £	Restricted funds £	2020 Total funds £	2019 Total funds £
Current assets	267,125	323,597	590,722	480,021
Current liabilities	<u>(255,475)</u>	<u>-</u>	<u>(255,475)</u>	<u>(177,342)</u>
	<u>11,650</u>	<u>323,597</u>	<u>335,247</u>	<u>302,679</u>

Notes to the Financial Statements - continued
for the Year Ended 31st December 2020

14. MOVEMENT IN FUNDS

	At 1.1.20 £	Net movement in funds £	At 31.12.20 £
Unrestricted funds			
General fund	124,112	(112,551)	11,561
Parkinson's Life	<u>(4,200)</u>	<u>4,289</u>	<u>89</u>
	119,912	(108,262)	11,650
Restricted funds			
PDCS	30,637	7,814	38,451
Research/Clinical trials	-	34,008	34,008
Parkinson's Information	7,487	(7,487)	-
Data Collection	12,498	(131)	12,367
Treat ER	91,752	(4,046)	87,706
European Young Onset PD	40,393	462	40,855
Advanced therapies	-	13,103	13,103
AirLiquide Carers Project	-	25,665	25,665
Brain Life Goals	-	2,529	2,529
Bial	-	12,091	12,091
HCP Info/Educational Materials	-	8,786	8,786
Parkinson Sleep Project	-	27,252	27,252
Parkinson's Games	-	3,186	3,186
Tshipi's Art Exhibition	-	3,043	3,043
WPC Barcelona 2020	<u>-</u>	<u>14,555</u>	<u>14,555</u>
	<u>182,767</u>	<u>140,830</u>	<u>323,597</u>
TOTAL FUNDS	<u>302,679</u>	<u>32,568</u>	<u>335,247</u>

European Parkinson's Disease Association

Notes to the Financial Statements - continued for the Year Ended 31st December 2020

14. MOVEMENT IN FUNDS - continued

Net movement in funds, included in the above are as follows:

	Incoming resources £	Resources expended £	Gains and losses £	Movement in funds £
Unrestricted funds				
General fund	315,855	(424,721)	(3,685)	(112,551)
Parkinson's Life	<u>65,200</u>	<u>(67,809)</u>	<u>6,898</u>	<u>4,289</u>
	381,055	(492,530)	3,213	(108,262)
Restricted funds				
PDCS	9,804	(1,992)	2	7,814
Research/Clinical trials	37,339	(3,331)	-	34,008
Parkinson's Information	2,247	(2,836)	(6,898)	(7,487)
Data Collection	-	(131)	-	(131)
Treat ER	-	-	(4,046)	(4,046)
European Young Onset PD	2,693	(2,231)	-	462
Advanced therapies	13,103	-	-	13,103
AirLiquide Carers Project	29,731	(4,066)	-	25,665
Brain Life Goals	2,705	(176)	-	2,529
Bial	15,721	(3,630)	-	12,091
HCP Info/Educational Materials	9,035	(249)	-	8,786
Parkinson Sleep Project	29,418	(2,166)	-	27,252
Parkinson's Games	4,260	(1,074)	-	3,186
Tshipi's Art Exhibition	3,361	(318)	-	3,043
WPC Barcelona 2020	<u>19,493</u>	<u>(4,938)</u>	<u>-</u>	<u>14,555</u>
	<u>178,910</u>	<u>(27,138)</u>	<u>(10,942)</u>	<u>140,830</u>
TOTAL FUNDS	<u>559,965</u>	<u>(519,668)</u>	<u>(7,729)</u>	<u>32,568</u>

Comparatives for movement in funds

	At 1.1.19 £	Net movement in funds £	At 31.12.19 £
Unrestricted funds			
General fund	95,309	28,803	124,112
Parkinson's Life	<u>-</u>	<u>(4,200)</u>	<u>(4,200)</u>
	95,309	24,603	119,912
Restricted funds			
PDCS	51,115	(20,478)	30,637
Parkinson's Information	1,168	6,319	7,487
Data Collection	12,498	-	12,498
Treat ER	91,752	-	91,752
European Young Onset PD	<u>29,621</u>	<u>10,772</u>	<u>40,393</u>
	<u>186,154</u>	<u>(3,387)</u>	<u>182,767</u>
TOTAL FUNDS	<u>281,463</u>	<u>21,216</u>	<u>302,679</u>

Notes to the Financial Statements - continued
for the Year Ended 31st December 2020

14. MOVEMENT IN FUNDS - continued

Comparative net movement in funds, included in the above are as follows:

	Incoming resources £	Resources expended £	Gains and losses £	Movement in funds £
Unrestricted funds				
General fund	271,547	(240,459)	(2,285)	28,803
Parkinson's Life	-	(4,200)	-	(4,200)
	271,547	(244,659)	(2,285)	24,603
Restricted funds				
PDCS	-	(20,478)	-	(20,478)
Parkinson's Information	8,696	(2,377)	-	6,319
European Young Onset PD	13,103	(2,331)	-	10,772
Advanced therapies	13,103	(13,103)	-	-
AirLiquide Carers Project	2,444	(2,444)	-	-
Parkinson's Life	57,310	(57,310)	-	-
	94,656	(98,043)	-	(3,387)
TOTAL FUNDS	<u>366,203</u>	<u>(342,702)</u>	<u>(2,285)</u>	<u>21,216</u>

15. RELATED PARTY DISCLOSURES

There were no related party transactions for the year ended 31st December 2020.

European Parkinson's Disease Association

Detailed Statement of Financial Activities **for the Year Ended 31st December 2020**

	2020 £	2019 £
INCOME AND ENDOWMENTS		
Donations and legacies		
Members fees	23,904	24,408
Donations	<u>4,379</u>	<u>2,218</u>
	28,283	26,626
Charitable activities		
Member organisation meeting	-	22,374
Publication income	-	6,774
Investments	174	313
Other income	-	1,895
Core income	531,508	255,664
Project income	<u>-</u>	<u>52,557</u>
	<u>531,682</u>	<u>339,577</u>
Total incoming resources	559,965	366,203
EXPENDITURE		
Charitable activities		
Members meeting	7,246	38,052
Administration Board	22,105	31,991
PDG think tank	-	2,171
Website	9,690	7,922
Parkinson's life	72,009	58,392
Exhibitions	1,539	12,999
Communications	14,185	10,050
Social media	6,629	20,470
Digital strategy	6,083	10,228
Member organisation outreach	10,273	11,934
GDPR	540	1,076
PDCS	2,946	28,089
Research/clinical trials	3,331	1,550
Parkinson's info	2,836	2,748
Data collection	131	1,812
Global campaign	-	2,404
Treat ER	8,220	250
EYOPD	2,231	2,380
Advocacy	161,744	1,877
AirLiquide carers project	4,066	28,557
Adviser	16,194	1,547
Prevalence	302	-
Merz (survey/HCP awareness)	3,017	-
Medtronic Awareness projects	309	-
HCP info/education materials	249	-
Carried forward	355,875	276,499

This page does not form part of the statutory financial statements

European Parkinson's Disease Association**Detailed Statement of Financial Activities**
for the Year Ended 31st December 2020

	2020 £	2019 £
Charitable activities		
Brought forward	355,875	276,499
Awareness campaigns	2,202	-
Brain life goals	176	-
Bial's	3,630	-
Servier patient insights works	2,838	-
Kyowa kirin	289	-
Abbott	39	-
AbbVie	228	-
Boston affiliates	18	-
Britannia (awareness)	507	-
CMS	2,208	-
EPDA industry meeting	2,048	-
Industry partnered projects	3,177	-
Medtronic partnered project	147	-
NeuroPath EU project	612	-
Parkinson sleep project	2,166	-
Parkinson's games	1,074	-
Sunovion research project	3,346	-
Tshipi's art exhibition	318	-
WPC Barcelona	4,938	-
	385,836	276,499
Other		
Rent	1,326	-
Support costs		
Management		
Advertising	3,142	-
Fundraising	5,637	14,926
	8,779	14,926
Finance		
Wages	25,099	8,693
Bank charges	178	-
Financial administration	30,818	15,326
Accountancy fees	5,000	4,760
Bookkeeping costs	4,000	-
	65,095	28,779
Other		
General expenditure	12,714	13,062
Administration costs	44,918	8,436
	57,632	21,498
Governance costs		
Independent examination costs	1,000	1,000

This page does not form part of the statutory financial statements

European Parkinson's Disease Association

Detailed Statement of Financial Activities
for the Year Ended 31st December 2020

	2020 <u>£</u>	2019 <u>£</u>
Total resources expended	<u>519,668</u>	<u>342,702</u>
Net income before gains and losses	40,297	23,501
Realised recognised gains and losses		
Realised gains/(losses) on fixed asset investments	<u>(7,729)</u>	<u>(2,285)</u>
Net income	<u><u>32,568</u></u>	<u><u>21,216</u></u>

**Statement of Financial Activities for
the Year Ended 31st December 2020**

	2020 (£)	2020 (€)	2019 (£)	2019 (€)
INCOME AND ENDOWMENTS				
Donations				
Members Fees	23,904	26,709	24,408	28,844
Donations	<u>4,379</u>	<u>4,893</u>	<u>2,218</u>	<u>2,621</u>
	28,283	31,602	26,626	31,465
Charitable Activities				
Member organisation meeting	-	-	22,374	26,440
Publication Income	-	-	6,774	8,005
Investments	174	194	313	370
Other income	-	-	1,895	2,239
Core income	531,508	593,882	255,664	302,131
Project income	<u>-</u>	<u>-</u>	<u>52,557</u>	<u>62,109</u>
	<u>531,682</u>	<u>594,077</u>	<u>339,577</u>	<u>401,294</u>
Total incoming resources	559,965	625,679	366,203	432,759
EXPENDITURE				
Charitable activities				
Members meeting	7,246	8,096	38,052	44,968
Administration Board	22,105	24,699	31,991	37,805
PDG think tank	-	2,566	2,171	2,566
Website	9,690	10,827	7,922	9,362
Parkinson's life	72,009	80,460	58,392	69,005
Exhibitions	1,539	1,720	12,999	15,362
Communications	14,185	15,850	10,050	11,877
Social Media	6,629	7,407	20,470	24,190
Digital strategy	6,083	6,797	10,228	12,087
Member organisation outreach	10,273	11,479	11,934	14,103
GDPR	540	603	1,076	1,272
PDCS	2,946	3,292	28,089	33,194
Research/clinical trials	3,331	3,720	1,550	1,832
Parkinson's info	2,836	3,169	2,748	3,247
Data collection	131	146	1,812	2,141
Global campaign	-	-	2,404	2,841
Treat ER	8,220	9,185	250	295
EYOPD	2,231	2,493	2,380	2,813
Advocacy	161,744	180,725	1,877	2,218
AirLiquide carers project	4,066	4,543	28,557	33,747
Adviser	16,194	18,094	1,547	1,828
Prevalence	302	337	-	-
Merz (survey/HCP awareness)	3,017	3,371	-	-
Medtronic Awareness projects	309	345	-	-
HCP info/education materials	249	278	-	-
Carried forward	355,875	397,638	276,499	326,753

This page does not form part of the statutory financial statements

European Parkinson's Disease Association

Statement of Financial Activities for the Year Ended 31st December 2020

Charitable activities

Brought forward	355,875	397,638	276,499	326,753
Awareness campaigns	2,202	2,460	-	-
Brain life goals	176	197	-	-
Bial's	3,630	4,056	-	-
Servier patient insights works	2,838	3,171	-	-
Kyowa kirin	289	323	-	-
Abbott	39	44	-	-
AbbVie	228	255	-	-
Boston affiliates	18	20	-	-
Britannia (awareness)	507	566	-	-
CMS	2,208	2,467	-	-
EPDA industry meeting	2,048	2,288	-	-
Industry partnered projects	3,177	3,550	-	-
Medtronic partnered project	147	164	-	-
NeuroPath EU project	612	684	-	-
Parkinson sleep project	2,166	2,420	-	-
Parkinson's games	1,074	1,200	-	-
Sunovion research project	3,346	3,739	-	-
Tshipi's art exhibition	318	355	-	-
WPC Barcelona	<u>4,938</u>	<u>5,517</u>	-	-
	385,836	431,115	276,499	326,753

Other

Rent	1,326	1,482	-	-
------	-------	-------	---	---

Support costs

Management

Advertising	3,142	3,511	-	-
Fundraising	<u>5,637</u>	<u>6,299</u>	-	-
	8,779	9,809	-	-

Finance

Wages	25,099	28,044	8,693	10,273
Bank charges	178	199	-	-
Financial administration	30,818	34,435	15,326	18,112
Accountancy fees	5,000	5,587	4,760	5,625
Bookkeeping costs	<u>4,000</u>	<u>4,469</u>	-	-
	65,095	72,734	28,779	34,010

Other

General expenditure	12,714	14,206	13,062	15,436
Administration costs	<u>44,918</u>	<u>50,189</u>	<u>8,436</u>	<u>9,969</u>
	57,632	64,395	21,498	25,405

Governance costs

Independent examination costs	1,000	1,117	1,000	1,182
-------------------------------	-------	-------	-------	-------

European Parkinson's Disease Association

**Statement of Financial Activities for
the Year Ended 31st December 2020**

Total resources expended	<u>519,668</u>	<u>580,653</u>	<u>342,702</u>	<u>404,988</u>
Net income before gains and losses	40,297	45,026	23,501	27,772
Realised recognised gains and losses				
Realised gains/(losses) on fixed asset investments	<u>(7,729)</u>	<u>(8,636)</u>	<u>(2,285)</u>	<u>(2,700)</u>
Net income	<u>32,568</u>	<u>36,390</u>	<u>21,216</u>	<u>25,072</u>

European Parkinson's Disease Association

**Statement of Financial Position for
the Year Ended 31st December 2020**

	2020 (£)	2020 (€)	2019 (£)	2019 (€)
CURRENT ASSETS				
Debtors	133,500	149,167	68,704	81,191
Cash at bank and in hand	<u>457,222</u>	<u>510,879</u>	<u>411,317</u>	<u>486,074</u>
	590,722	660,045	480,021	567,265
CREDITORS				
Amounts falling due within one year	(255,475)	(285,456)	(177,342)	(209,574)
NET CURRENT ASSETS	<u>335,247</u>	<u>374,589</u>	<u>302,679</u>	<u>357,691</u>
TOTAL ASSETS LESS CURRENT LIABILITIES	335,247	374,589	302,679	357,691
NET ASSETS				
FUNDS				
Unrestricted funds	11,650	13,017	124,112	146,669
Restricted funds	<u>323,597</u>	<u>361,572</u>	<u>178,567</u>	<u>211,022</u>
TOTAL FUNDS	<u>335,247</u>	<u>374,589</u>	<u>302,679</u>	<u>357,691</u>